Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study

Autor: Núria Rudi, Ana Sogo, Ignacio Dávila, Christian Domingo, Albert Navarro, Rosa Mirapeix, Xavier Pomares
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Exacerbation
alergia e inmunología
Administration
Oral
Omalizumab
Immunoglobulin E
Severity of Illness Index
lcsh:Chemistry
Leukocyte Count
0302 clinical medicine
Adrenal Cortex Hormones
immune system diseases
severe allergic asthma
030212 general & internal medicine
Anti-Asthmatic Agents
lcsh:QH301-705.5
Spectroscopy
pathophysiology
biology
medicine.diagnostic_test
General Medicine
Middle Aged
respiratory system
Computer Science Applications
Respiratory Function Tests
Treatment Outcome
Exhalation
Disease Progression
Corticosteroid
Female
Seasons
medicine.drug
Spirometry
Adult
medicine.medical_specialty
Severe allergic asthma
medicine.drug_class
Nitric Oxide
Pathophysiology
Catalysis
Article
Inorganic Chemistry
03 medical and health sciences
FEV1/FVC ratio
Internal medicine
Allergy and Immunology
medicine
Humans
Physical and Theoretical Chemistry
Molecular Biology
Asthma
Aged
Skin Tests
perennial
Seasonal
business.industry
seasonal
omalizumab
Organic Chemistry
Allergens
medicine.disease
Perennial
respiratory tract diseases
Eosinophils
030228 respiratory system
lcsh:Biology (General)
lcsh:QD1-999
Exhaled nitric oxide
Immunology
biology.protein
business
Zdroj: International Journal of Molecular Sciences, Vol 18, Iss 3, p 521 (2017)
International Journal of Molecular Sciences
GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
International Journal of Molecular Sciences; Volume 18; Issue 3; Pages: 521
ISSN: 1422-0067
Popis: [EN] Omalizumab is marketed for chronic severe asthma patients who are allergic to perennial allergens. Our purpose was to investigate whether omalizumab is also effective in persistent severe asthma due to seasonal allergens. Thirty patients with oral corticosteroid-dependent asthma were treated with Omalizumab according to the dosing table. For each patient with asthma due to seasonal allergens, we recruited the next two consecutive patients with asthma due to perennial allergens. The dose of oral methyl prednisolone (MP) was tapered at a rate of 2 mg every two weeks after the start of treatment with omalizumab depending on tolerance. At each monthly visit, a forced spirometry and fractional exhaled nitric oxide (FeNO) measurement were performed and the accumulated monthly MP dose was calculated. At entry, there were no differences between groups in terms of gender, body mass index or obesity, year exacerbation rate, monthly dose of MP, FeNO and blood immunoglobuline E (IgE) values, or spirometry (perennial: FVC: 76%; FEV1: 62%; seasonal: FVC: 79%; FEV1: 70%). The follow-up lasted 76 weeks. One patient in each group was considered a non-responder. Spirometry did not worsen in either group. There was a significant intragroup reduction in annual exacerbation rate and MP consumption but no differences were detected in the intergroup comparison. Omalizumab offered the same clinical benefits in the two cohorts regardless of whether the asthma was caused by a seasonal or a perennial allergen. These results strongly suggest that allergens are the trigger in chronic asthma but that it is the persistent exposure to IgE that causes the chronicity.
Databáze: OpenAIRE
Externí odkaz: